Details of the Drug
General Information of Drug (ID: DMLT01H)
Drug Name |
6-Bromo-2-piperazin-1-yl-quinoline
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
124782-95-2; 6-Bromo-2-piperazin-1-yl-quinoline; 6-bromo-2-(piperazin-1-yl)quinoline; 6-Bromoquipazine; 6-bromo-2-piperazin-1-ylquinoline; Quinoline, 6-bromo-2-(1-piperazinyl)-; CHEMBL39164; Quinoline,6-bromo-2-(1-piperazinyl)-; ACMC-20mr6z; AC1L2X2K; SCHEMBL5912936; CTK4B4077; DTXSID90154485; MKIHFWMBAKJYJL-UHFFFAOYSA-N; ZINC2527449; BDBM50090213; 6-bromo-2-(1-piperazinyl)quinoline; 3453AJ; AKOS022401899; AB19846; 6-bromanyl-2-piperazin-1-yl-quinoline; AJ-83658; DB-062320; AX8027344; FT-0713002; Z-6757; A805296
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 292.17 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||